Brief: Brainstorm Secures Key Manufacturing Partnership With Minaris For Upcoming Nurown Phase 3B Als Clinical Trials
27/05/2025 13:07
May 27 (Reuters) - Brainstorm Cell Therapeutics Inc BCLI.O: BRAINSTORM SECURES KEY MANUFACTURING PARTNERSHIP WITH MINARIS FOR UPCOMING NUROWN® PHASE 3B ALS CLINICAL TRIALS Source text: ID:nPn2nQx2Fa Further company coverage: BCLI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview